

## CURRICULUM VITÆ



**Name** (First, Middle Initial, Last and Academic Qualification(s))

Aziz ZAANAN, MD, PhD

**Address** (Name of Institution, Street, Postal Code, City, Country)

Hôpital Européen Georges Pompidou  
Service d'Hépatogastroentérologie et Oncologie digestive  
20 rue Leblanc  
75015 Paris  
FRANCE

**Area Code and Number**

Phone : + 33 1 49 09 50 64  
Fax : + 33 1 49 09 50 69

**Education and Training**

<i>Name of Institution and Location</i>	<i>Degree and Year Conferred</i>	<i>Area of Study</i>
University of Paris, France	M.D. diploma, 2008	Medicine
University of Paris XII, France	Specialized post-graduate diploma, 2008	Hepatology and Gastroenterology
University of Paris XII, France	Diploma of complementary specialization, 2009	Oncology
University of Paris VII, France	Inter University diploma, 2011	Oncogenetic
University of Paris VI, France	Ph.D. diploma, 2011	Science
University of Paris V, France	HDR. diploma, 2018	Biomarkers in GI cancer

**Professional Experience** (Current and Previous Positions)

<i>Position</i>	<i>Institution/Employer and Location</i>	<i>Dates</i>	
Resident	Departments of Hepatology and Gastroenterology, Paris, France	<i>From:</i>	11/2003
		<i>To:</i>	10/2008
Chief Resident	Department of Medical Oncology, Saint Antoine Hospital, Paris, France	<i>From:</i>	11/2008
		<i>To:</i>	10/2010
Practitioner attached	Department of Genetics, Georges Pompidou Hospital, Paris, France	<i>From:</i>	11/2010
		<i>To:</i>	10/2011
Chief Resident	Department of Digestive Oncology, Georges Pompidou Hospital, Paris, France	<i>From:</i>	11/2011
		<i>To:</i>	10/2013
Research Fellow (Post doc)	Gastroenterology Research Unit, Mayo Clinic, Rochester MN, USA	<i>From:</i>	11/2013
		<i>To:</i>	10/2014
Assistant Professor	Department of Digestive Oncology, Georges Pompidou Hospital, Paris, France	<i>From:</i>	11/2014
		<i>To:</i>	08/2020
Professor	Department of Digestive Oncology, Georges Pompidou Hospital, Paris, France	<i>From:</i>	09/2020
		<i>To:</i>	

**Professional Memberships**

- Member of « Fédération Francophone de la Cancérologie Digestive » (FFCD), from 05/2011
- Chairman of « Association des Gastro-Entérologues Oncologues » (AGEO), from 12/2011
- Member of « Société Nationale Française Gastroentérologie » (SNFGE), from 02/2013

**Research Interests**

- 1 – Clinical research in gastrointestinal cancer
- 2 – Genetic and Genomic profiling to predict clinical outcome in colorectal and gastric cancer
- 3 – Therapeutic management and molecular biology of small bowel adenocarcinoma

## CURRICULUM VITÆ

### List of the 10 major selected peer-reviewed publications

1. Clinical outcome among MSI colon cancer patients of sporadic or familial origin treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of PETACC8 and N0147 trials. **Zaanan A**, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. JCO Precision Oncology 2020.
2. Immunotherapy in advanced gastric cancer, is it the future? Coutzac C, Pernot S, Chaput N, **Zaanan A**. Crit Rev Oncol Hematol. 2019;133:25-32. IF = 5.0
3. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. **Zaanan A**, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. JAMA Oncol. 2018 Mar 1;4(3):379-383. IF = 20.9
4. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, **Zaanan A**. Clin Cancer Res. 2017;23(18):5416-5425. IF = 10.2
5. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: A large multicenter AGEO study. Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, **Zaanan A**. J Natl Cancer Inst. 2016;108(7). IF = 12.5
6. MMR status influences the prognosis of BRAF and KRAS exon 2 mutations in stage III colon cancer patients treated with FOLFOX +/- cetuximab: a post-hoc analysis of PETACC8 trial. **Zaanan A**\*, Taieb J\*, Le Malicot K\*, Julie C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P. \*Equally contributed as first authors. JAMA Oncol. 2016;14:1-11. IF = 20.9
7. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. **Zaanan A**, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Rosmorduc O, Bonnetain F, Boige V, Taïeb J. J Hepatol. 2013;58:81-8. IF = 18.9
8. Defective Mismatch Repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. **Zaanan A**, Fléjou JF, Emile JF, Des Guetz G, Cuillière-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J. Clin Cancer Res. 2011;17:7470-8. IF = 10.2
9. Chemotherapy of advanced small bowel adenocarcinoma: A multicenter AGEO study. **Zaanan A**, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taieb J, Bonnetain F, Aparicio T. Ann Oncol 2010;21:1786-93. IF = 14.2
10. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin. **Zaanan A**, Cuillière-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F. Ann Oncol 2010; 21:772-80. IF = 14.2